by Elizabeth Kissling | Apr 22, 2010 | Birth Control, Disposable menstrual products, Menstruation, New Research, Pharmaceutical
So here’s an odd little study: when women are given a choice between oral contraceptives and the contraceptive vaginal ring, what characteristic is most highly correlated with a slightly greater interest in using the vaginal ring? If you said “tampon...
by Laura Wershler | Apr 20, 2010 | Birth Control, Newspapers, Pharmaceutical, Philosophy
I read The Birth-Control Riddle by Melinda Beck, published today in The Wall Street Journal with interest and frustration. As a veteran pro-choice sexual and reproductive health advocate, I’ve spent decades contemplating this “riddle”. I have two specific...
by Chris Hitchcock | Apr 20, 2010 | Birth Control, Health Care, Menstruation, Ovulation, Pharmaceutical, Reproduction, Sex
It’s starting. With the approaching 50th anniversary of the birth control pill, there will be a flood of anniversary celebrations and reviews of birth control methods. Which is good. We should have those discussions more often. Just say “no” (on the...
by Elizabeth Kissling | Apr 19, 2010 | Menopause, New Research, Newspapers, Pharmaceutical
Guest Post by Jerilynn C. Prior, Centre for Menstrual Cycle and Ovulation Research I just read “The Estrogen Dilemma” in Sunday’s New York Times Magazine, and I feel like weeping—in sorrow and deep sadness. This article by Cynthia Gorney is about energetic,...
by Elizabeth Kissling | Apr 18, 2010 | Menopause, New Research, Newspapers, Pharmaceutical
Guest Post by Paula S. Derry, Ph.D. Déjà vu An article in today’s New York Times Magazine recounts the author’s experience with a debilitating depression that began during her perimenopause, the transitional time leading up to menopause. For her, prescription...
by Elizabeth Kissling | Apr 3, 2010 | Birth Control, Menstruation, New Research, Pharmaceutical
We’ve mentioned Yaz and its sister drug Yasmin before, and our friend Holly Grigg-Spall tracks the progress of complaints against them and other oral contraceptives. Yaz and Yasmin were Bayer’s top-selling drugs in 2008, bringing in about $1.8 billion, a 17...
